Among thousands of applicants from all across Europe we are the only Czech company to receive both phase 1 and phase 2 of the H2020 SME Instrument grant.
This project closes the gap between our knowledge and expertise on protein engineering and the commercial applications of stable fibroblast growth factors (FGFs). FGFs are essential to embryonic development, maintaining tissue homeostasis, and may slow down ageing of organisms, and primarily promote angiogenesis and wound healing. FGFs’ greatest application can be found in the care and treatment of chronic skin ulcers, but are also used in surgical and traumatic wound healing.
The global wound-care market is rapidly growing due to the rising aging population and growing incidences of obesity and diabetes. Advanced wound dressings, such as those involving growth factors, play an important role in the current regenerative medicine. Growth factor-based products are on the rise.
Despite their clinical value, applications of FGFs are limited by the fact that natural proteins have poor thermal stability. They are often cleared from the body within hours, if not minutes, thus necessitating frequent administrations during the course of treatment. That goes hand in hand with a higher risk of adverse effects and lower cost-effectiveness of the protein therapy.
The key objective of this project is to apply our proprietary protein optimization concept to increase FGF stability under various stress conditions. And to conduct preclinical trial focused on the application of stabilized FGF2, which we already produced, in acute and chronic wounds (and more).
Additional challenges include lowering the cost of production, implementing Good Manufacturing Practices, and developing delivery systems for safe and effective wound healing.
We are grateful for both financial and coaching support provided by SME Instrument. It helps us to get things done faster and deliver products that wound care market has been waiting for.
FGFSTAB is co-funded by the Horizon 2020 Framework Programme
of the European Commission under GA No. 756471.